| Hisamitsu Charts the Future of Topical Patches with Salonpas | |
| by Donald Riker PhD | Date: Jan 26, 2010 |
Hisamitsu Pharma filed a citizens petition at FDA on 31 December 2009 [received 1/6/10] to remind the FDA to protect its investment in the first and only FDA-approved topical pain relieving patch, Salonpas. Over the last year Hisamitsu, the maker of Salonpas topical pain patches, has quietly charted the direction of pain relieving topical patches in the United States while others have been less than proactive.
Find out how & why ...











ssued a formal warning to J&J after an audit of its Puerto Rican plant. While J&J failed to react and withheld information from FDA for well over a year millions of consumers were exposed to a little-known chemical contaminant. Worse in a guarded, carefully worded press release Friday J&J chose not to identify the brand names affected either in the text or the title of its press release instead resorting to a lengthy separate pdf attachment. That fourt
een page attachment testifies to the extent and complexity of the recall as does a new website dedicated to the recall. In fact, consumers must work through the fine print to get the information they need. As it turns out 53 million bottles of pills are being recalled across iconic brands such as Tylenol, Rolaids, Benedryl and Motrin, or one bottle for every five adult consumers in the U.S. Over the last two years J&J, P&G and Chattem (Sanofi) have received warning letters concerning serious quality failures causing injury to consumers buying OTC branded products. If iconic brand names no longer provide an assurance of safety why take a chance with Tylenol, or any OTC brand, with cheaper store brands widely available?





